| Literature DB >> 35206569 |
Shanguang Zhao1, Aiping Chi1, Bingjun Wan1, Jian Liang2.
Abstract
Studies have found that the prevalence of chronic fatigue syndrome (CFS) in adolescents has continued to increase over the years, affecting learning and physical health. High school is a critical stage for adolescents to grow and mature. There are inadequate detection and rehabilitation methods for CFS due to an insufficient understanding of the physiological mechanisms of CFS. The purpose of this study was to evaluate the effect and metabolic mechanisms of an aerobic running intervention program for high school students with CFS. Forty-six male high school students with CFS were randomly assigned to the exercise intervention group (EI) and control group (CFS). Twenty-four age- and sex-matched healthy male students were recruited as healthy controls (HCs). The EI group received the aerobic intervention for 12 weeks, three times a week, in 45-min sessions; the CFS group maintained their daily routines as normal. The outcome measures included fatigue symptoms and oxidation levels. Keratin was extracted from the nails of all participants, and the oxidation level was assessed by measuring the content of 3-Nitrotyrosine (3-NT) in the keratin by ultraviolet spectrophotometry. All participants' morning urine was collected to analyze urinary differential metabolites by the GC-MS technique before and after the intervention, and MetaboAnalyst 5.0 was used for pathway analysis. Compared with before the intervention, the fatigue score and 3-NT level in the EI group were significantly decreased after the intervention. The CFS group was screened for 20 differential metabolites involving the disruption of six metabolic pathways, including arginine biosynthesis, glycerolipid metabolism, pentose phosphate pathway, purine metabolism, β-alanine metabolism, and arginine and proline metabolism. After the intervention, 21 differential metabolites were screened, involved in alterations in three metabolic pathways: beta-alanine metabolism, pentose phosphate metabolism, and arginine and proline metabolism. Aerobic exercise was found to lessen fatigue symptoms and oxidative levels in students with CFS, which may be related to the regulation of putrescine (arginine and proline metabolism), 6-Phospho-D-Gluconate (starch and sucrose metabolism pathway), and Pentose (phosphate metabolism pathway).Entities:
Keywords: adolescent; aerobic exercise; chronic fatigue syndrome; metabolomics; middle school student
Mesh:
Year: 2022 PMID: 35206569 PMCID: PMC8872503 DOI: 10.3390/ijerph19042377
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Demographic information of participants (Mean ± SD).
| Variable | CFS ( | EI ( | HCs ( |
|---|---|---|---|
| Age, years | 16.72 ± 0.41 | 16.57 ± 0.28 | 16.42 ± 0.74 |
| Height, cm | 176.30 ± 1.37 | 174.50 ± 1.24 | 176.50 ± 1.47 |
| Weight, kg | 71.46 ± 1.73 | 69.24 ± 2.41 | 68.65 ± 3.58 |
| BMI, kg/m2 | 22.25 ± 1.12 | 22.46 ± 1.31 | 22.92 ± 0.60 |
Note: CFS, chronic fatigue syndrome group; HCs, healthy controls; EI, exercise intervention group.
FS-14 results between the CFS and EI groups before and after the intervention.
| Baseline | 12 Weeks | |||
|---|---|---|---|---|
| EI | CFS | CFS | EI | |
| Total fatigue score | 10.72 ± 0.14 | 10.14 ± 0.14 | 8.46 ±0.16 | 4.36 ± 0.16 ***### |
| Physical fatigue score | 5.18 ± 0.12 | 5.05 ± 0.18 | 4.41 ± 0.22 | 2.13 ± 0.15 ***### |
| Mental fatigue score | 5.22 ± 0.18 | 5.09 ± 0.12 | 4.05 ± 0.15 | 2.22 ± 0.22 ***### |
Note: ### indicates compared with EI group at 12 weeks, p < 0.001; *** indicates compared with baseline, p < 0.001.
Figure 13-NT content of nails before and after the intervention. Note: * indicates statistical significance (p < 0.05).
Figure 2PCA scores plot of urine samples from all samples.
Figure 3OPLS-DA scores plot and validation of OPLS-DA model by permutation test. (a) CFS vs. HC (b) EI vs. CFS. The above scatter plot of the OPLS-DA model shows obvious discrimination between CFS students (blue box) versus HCs (yellow ball) in the baseline period and CFS versus EI (red ball) after the intervention. The following is the permutation test chart. Validation of OPLS-DA model of urinary samples by permutation test (the x-axis means the correlation coefficient between the original y variable and the permutated y variable), and the y-axis is the value of R2 and Q2.
Differential metabolites in the CFS group compared within the HCs (group CFS vs. group HCs).
| Metabolite | HMDB ID | RT (min) | VIP | FC | ||
|---|---|---|---|---|---|---|
| Uric acid | HMDB0000289 | 20.02 | 55 | 3.17 | 0.00001 | 3.35 |
| D-Glyceric acid | HMDB0000139 | 11.34 | 71 | 1.36 | 0.01121 | 2.00 |
| Lactose | HMDB0041627 | 24.98 | 64 | 2.56 | 0.00001 | 2.68 |
| 4-hydroxyphenylacetic acid | HMDB0000020 | 15.31 | 179 | 2.3 | 0.00009 | 0.45 |
| N-Acetyl-L-glutamic acid | HMDB0001138 | 15.74 | 117 | 2.87 | 0.00000 | 8.47 |
| 3,4-Dihydroxyphenylacetic acid | HMDB0001336 | 17.36 | 179 | 2.68 | 0.00003 | 3.29 |
| N-Acetylglutamic acid | HMDB0001138 | 16.89 | 84 | 2.89 | 0.00000 | 2.91 |
| D-(glycerol 1-phosphate) | HMDB0000126 | 16.60 | 292 | 2.98 | 0.00000 | 5.61 |
| Inosine | HMDB0000195 | 23.99 | 230 | 1.26 | 0.00826 | 0.38 |
| Purine riboside | HMDB0029956 | 22.35 | 103 | 3.02 | 0.00000 | 5.36 |
| Beta-Alanine | HMDB0000056 | 12.57 | 174 | 2.06 | 0.00192 | 2.73 |
| 6-phosphogluconic acid | HMDB0001316 | 22.70 | 217 | 2.50 | 0.00014 | 5.47 |
| N-Carbamylglutamate | HMDB0015673 | 19.46 | 174 | 1.44 | 0.01197 | 0.36 |
| 4-Androsten-11beta-ol-3,17-dione | HMDB0006773 | 26.82 | 361 | 1.29 | 0.01217 | 0.32 |
| Adrenaline | HMDB0000068 | 17.57 | 267 | 2.84 | 0.00262 | 2.35 |
| L-Dithiothreitol | HMDB0013593 | 15.00 | 195 | 2.05 | 0.00057 | 0.03 |
| Citrulline | HMDB0000904 | 16.52 | 71 | 1.45 | 0.01879 | 1.52 |
| Putrescine | HMDB0001414 | 16.59 | 72 | 2.87 | 0.00000 | 2.50 |
| Elaidic acid | HMDB0000573 | 21.29 | 131 | 1.45 | 0.01773 | 1.52 |
| 2,2-Dimethylsuccinic Acid | HMDB0002074 | 11.27 | 71 | 2.70 | 0.00000 | 2.81 |
Note: HMDB ID, the code in the HMDB database corresponding to the substance; RT, retention time of chromatographic peak; m/z, mass-to-charge ratio; VIP, the variable projection importance of the substance obtained in the OPLS-DA model compared in this group; FC, fold change refers to the ratio of the average metabolite; FC > 1, up-regulated; FC < 1, down-regulated.
Information on differential metabolites after 12 weeks of exercise intervention (group EI vs. group CFS).
| Metabolite | HMDB ID | RT (min) | VIP | FC | ||
|---|---|---|---|---|---|---|
| Oxalic acid | HMDB0002329 | 8.58 | 79 | 1.68 | 0.001044 | 0.76 |
| Cellobiose | HMDB0000055 | 24.96 | 79 | 1.00 | 0.014957 | 1.48 |
| Uric acid | HMDB0000289 | 20.02 | 55 | 1.90 | 0.000031 | 3.65 |
| Quinolinic acid | HMDB0000232 | 16.29 | 79 | 2.15 | 0.000772 | 0.63 |
| N-Acetylmannosamine | HMDB0001129 | 19.78 | 79 | 2.27 | 0.000533 | 0.64 |
| Lactose | HMDB0041627 | 24.98 | 38 | 2.38 | 0.000020 | 16.9 |
| Orotic acid | HMDB0000226 | 16.44 | 79 | 1.50 | 0.014485 | 0.74 |
| Glycerol 1-phosphate | HMDB0000126 | 16.60 | 46 | 2.23 | 0.009390 | 2.99 |
| L-Malic acid | HMDB0000156 | 13.42 | 76 | 1.05 | 0.035540 | 1.58 |
| Malonic acid | HMDB0000691 | 9.51 | 79 | 1.31 | 0.021348 | 1.36 |
| 3-Methylglutaric Acid | HMDB0000752 | 12.66 | 67 | 1.65 | 0.010768 | 0.62 |
| Purine riboside | HMDB0029956 | 22.35 | 48 | 2.97 | 0.000000 | 19.9 |
| Uridine | HMDB0000296 | 23.06 | 79 | 2.21 | 0.000191 | 0.72 |
| 6-phosphogluconic acid | HMDB0001316 | 22.70 | 32 | 1.97 | 0.002571 | 4.19 |
| 3-Hydroxypyridine acid | HMDB0013188 | 8.74 | 71 | 1.18 | 0.021134 | 1.62 |
| Citraconic acid | HMDB0000634 | 12.84 | 76 | 1.05 | 0.002329 | 0.65 |
| 5,6-dihydrouracil | HMDB0000076 | 15.10 | 41 | 1.08 | 0.028759 | 0.35 |
| Putrescine | HMDB0001414 | 21.95 | 57 | 2.11 | 0.000006 | 0.22 |
| Glucose-6-phosphate | HMDB0001401 | 23.43 | 39 | 1.74 | 0.018920 | 0.22 |
| 2,2-Dimethylsuccinic Acid | HMDB0002074 | 11.27 | 31 | 2.18 | 0.001279 | 0.48 |
Note: HMDB ID, the code in THE HMDB database corresponding to the substance; RT, retention time of chromatographic peak; m/z, mass-to-charge ratio; VIP, the variable projection importance of the substance obtained in the OPLS-DA model compared in this group; FC, fold change refers to the ratio of the average metabolite; FC > 1, up-regulated; FC < 1, down-regulated.
Figure 4Topological score results of the metabolic pathway. (a) is a comparison of the HCs and CFS groups: A beta-alanine metabolism; B arginine biosynthesis; C Glycerolipid metabolism; D Pentose phosphate pathway; E Arginine and proline metabolism. (b) is a comparison of the EI and CFS groups after the intervention: A Starch and sucrose metabolism; B Pentose phosphate metabolism; C Arginine and proline metabolism.
Figure 5Arginine and proline metabolism pathway. C00134 Putrescine; 1,4-Butanediamine; 1,4-Diaminobutane; Tetramethylenediamine; Butane-1,4-diamine.
Figure 6(a) Starch and sucrose metabolism pathway and (b) Pentose phosphate metabolism pathway (C00345/C00092 6-Phospho-D-gluconate).